OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector is pleased to announce today that the company’s lead product candidate Betalutin™ has been granted orphan-drug designation for treatment of follicular lymphoma in the USA by FDA’s Office of Orphan Products Development.
Orphan-drug designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as commercial exclusivity for seven years once the product reaches the market.
Help employers find you! Check out all the jobs and post your resume.
